Avadel Pharmaceuticals plc announced that Jordan Dubow, M.D. will be stepping down as chief medical officer to pursue another opportunity. He will continue in a consultancy role in order to support the company through the filing, review and anticipated approval of the new drug application (NDA) for FT218 with the FDA. Mark McCamish, M.D., Ph.D., an independent director on the company’s Board of Directors and an accomplished industry executive with over 30 years of drug development experience, will assume a direct leadership role for the FT218 filing working with the company CEO Greg Divis, Dr. Dubow and the rest of the team to ensure continuity of the FT218 program, including the completeness and timeliness of the NDA submission.